Balancing Treatment Intensification and Toxicity in Metastatic Castration Sensitive Prostate Cancer (mCSPC)

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce how clinicians balance the benefits of treatment intensification with the potential for added toxicity in patients with metastatic castration sensitive prostate cancer (mCSPC), particularly in older individuals or those with significant comorbidities. Dr. Bryce explains that while combination therapy has demonstrated meaningful survival advantages, patient selection remains critical. He emphasizes the need to carefully assess overall health status, comorbid conditions, and functional capacity when determining whether a patient can tolerate intensified therapy. The discussion highlights that clinicians must weigh the potential for improved disease control against risks such as treatment related adverse effects and the impact on quality of life. Dr. Bryce also notes the importance of shared decision making with patients, ensuring that treatment choices align with individual goals and expectations. The segment underscores how personalized assessment guides treatment strategies for complex patients with metastatic castration sensitive prostate cancer.